Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth
Update your Virtual Booth on PharmaCompass, ask us
About
CPhI India 2024CPhI India 2024
Not Confirmed
Not Confirmed
26-28 November, 2024
Not Confirmed
Not Confirmed
20-23 October, 2024
Not Confirmed
Not Confirmed
21-24 October, 2024
List your booth number for exhibitions, ask us
CONTACT DETAILS
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Events
Webinars & Exhibitions
CPhI India 2024CPhI India 2024
Industry Trade Show
Not Confirmed
26-28 November, 2024
Industry Trade Show
Not Confirmed
20-23 October, 2024
Industry Trade Show
Not Confirmed
21-24 October, 2024
Digital content
INTERVIEW #SpeakPharma
[Sponsored by another company]https://www.pharmacompass.com/speak-pharma/we-have-built-considerable-expertise-in-glp-1-drug-development-through-our-oral-peptide-programs
VLOG #PharmaReel
[Sponsored by another company]DATA COMPILATION #PharmaFlow
[Sponsored by another company]https://www.pharmacompass.com/radio-compass-blog/dmf-filings-hit-all-time-high-in-q3-2024-china-tops-list-with-58-increase-in-type-ii-submissions
03 Oct 2024
// PR NEWSWIRE
https://www.prnewswire.com/news-releases/resolution-therapeutics-announces-63-5-million-series-b-financing-and-chair-appointment-302265830.html
Details:
The proceeds will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy for the treatment of end-stage liver disease.
Lead Product(s): RTX001
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: RTX001
Study Phase: Phase I/ Phase IIProduct Type: Cell and Gene therapy
Sponsor: Syncona
Deal Size: $83.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing October 02, 2024
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase I/ Phase II
Partner/Sponsor/Collaborator : Syncona
Deal Size : $83.0 million
Deal Type : Series B Financing
Resolution Therapeutics Announces £63.5 Million Series B Financing and Chair Appointment
Details : The proceeds will be used to advance Resolution's lead candidate, RTX001, an autologous, engineered, pro-regenerative macrophage cell therapy for the treatment of end-stage liver disease.
Brand Name : RTX001
Molecule Type : Cell and Gene therapy
Upfront Cash : Undisclosed
October 02, 2024
Details:
RTX001 is an engineered autologous macrophage cell therapy designed to deliver anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease like decompensated liver cirrhosis.
Lead Product(s): RTX001
Therapeutic Area: Hepatology (Liver, Pancreatic, Gall Bladder) Brand Name: RTX001
Study Phase: IND EnablingProduct Type: Cell and Gene therapy
Sponsor: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 27, 2024
Lead Product(s) : RTX001
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : IND Enabling
Partner/Sponsor/Collaborator : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Resolution Therapeutics Gets MHRA Approval for Phase I/II EMERALD Study RTX001
Details : RTX001 is an engineered autologous macrophage cell therapy designed to deliver anti-fibrotic and anti-inflammatory effects in patients with end-stage liver disease like decompensated liver cirrhosis.
Brand Name : RTX001
Molecule Type : Cell and Gene therapy
Upfront Cash : Not Applicable
June 27, 2024
ABOUT THIS PAGE
LOOKING FOR A SUPPLIER?